Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)

Conditions

• Alopecia Areata

Eligibility Criteria

Sex

ALL

Age

12 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Ritlecitinib — DRUG
  capsules

Study Details

Provide pre-approval single patient Expanded Access (compassionate use) of Ritlecitinib for patients.

Key Dates

Status verified

Nov 2025

Central Contacts

• Pfizer Cares
  [email protected]

Related Studies

• Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
  PHASE2 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
• Regeneron AA Multicenter (Dupilumab)
  PHASE2 · Recruiting · Emma Guttman · Irvine, California
• CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry
  Recruiting · CorEvitas · Waltham, Massachusetts
• Dupilumab in the Treatment of Pediatric Alopecia Areata
  PHASE2 · Recruiting · Icahn School of Medicine at Mount Sinai · Irvine, California